The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy by Themistocleous, AC et al.
Research Paper
The Pain in Neuropathy Study (PiNS):
a cross-sectional observational study determining
the somatosensory phenotype of painful and
painless diabetic neuropathy
Andreas C. Themistocleousa, Juan D. Ramireza, Pallai R. Shillob, Jonathan G. Leesc, Dinesh Selvarajahb,
Christine Orengoc, Solomon Tesfayeb, Andrew S.C. Riced,e, David L.H. Bennetta,*
Abstract
Disabling neuropathic pain (NeuP) is a common sequel of diabetic peripheral neuropathy (DPN).We aimed to characterise the sensory
phenotype of patients with and without NeuP, assess screening tools for NeuP, and relate DPN severity to NeuP. The Pain in
NeuropathyStudy (PiNS) is an observational cross-sectionalmulticentre study. A total of 191patientswithDPNunderwent neurological
examination, quantitative sensory testing, nerve conduction studies, and skin biopsy for intraepidermal nerve fibre density assessment.
A set of questionnaires assessed the presence of pain, pain intensity, pain distribution, and the psychological and functional impact of
pain. Patientswere divided according to thepresence ofDPN, and thereafter according to thepresence and severity of NeuP. TheDN4
questionnaire demonstrated excellent sensitivity (88%) and specificity (93%) in screening for NeuP. There was a positive correlation
between greater neuropathy severity (r5 0.39, P, 0.01), higher HbA1c (r5 0.21,P, 0.01), and the presence (and severity) of NeuP.
Diabetic peripheral neuropathy sensory phenotype is characterised by hyposensitivity to applied stimuli that was more marked in the
moderate/severe NeuP group than in the mild NeuP or no NeuP groups. Brush-evoked allodynia was present in only those with NeuP
(15%); the paradoxical heat sensation did not discriminate between those with (40%) and without (41.3%) NeuP. The “irritable
nociceptor” subgroup could only be applied to a minority of patients (6.3%) with NeuP. This study provides a firm basis to rationalise
further phenotyping of painful DPN, for instance, stratification of patients with DPN for analgesic drug trials.
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1. Introduction
Diabetic peripheral neuropathy (DPN) is one of the most frequent
complications of diabetes mellitus46 and affects between 28%
and 49% of patients.1,53 Between 25% and 50% of patients with
DPN develop neuropathic pain (NeuP)1,8,50—defined as pain
arising as a consequence of a lesion or disease of the
somatosensory nervous system.26,48 This pain is typically localised
to the feet but can spread proximally with more advanced
disease.47 Although analgesic agents exist for the symptomatic
treatment of NeuP (including tricyclic antidepressants, serotonin–
norepinephrine reuptake inhibitors and gabapentinoids),12,21
treatment is often inadequate and NeuP has a subsequent major
deleterious impact on quality of life.17,24,50 Diabetic peripheral
neuropathy is one of the commonest causes of NeuP in the
community, and given the increasingprevalence of type 2 diabetes
mellitus, it will become even more frequent in the future.55
The pathophysiology of NeuP in DPN is complex and not fully
understood. The initial inciting event is a “dying back” axonopathy
principally affecting sensory neurons.12 It is believed that these
neurons become hyperexcitable as a consequence of altered
gene expression and posttranslational modification of key ion
channels.30,51 There are also changes with the central nervous
system, both at the level of the spinal cord and brain at an
anatomical and functional level leading to amplification of
nociceptive processing.45
In the last decade, significant advances in techniques to define
somatosensory phenotype in the context of NeuP have been
developed. These include questionnaires, such as DN4,6
painDETECT,22 and LANSS,4 designed to distinguish NeuP from
other types of pain using patient-reported pain descriptors (and in
some cases examination findings) and standardisation of
quantitative sensory testing (QST) (for instance, the standardised
protocol of the German Neuropathic Pain Network).38
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Quantitative sensory testing assesses evoked sensory percep-
tion in response to a defined sensory stimulus. This can be used
to test a range of sensory modalities including small-fibre sensory
function (eg, thermal and pain thresholds) and large-fibre
modalities (eg, vibration threshold).38
Application of these techniques has shown that NeuP is
a multidimensional entity, and there are distinct subgroups of
patients who have particular patterns of sensory symptoms and
signs. Such sensory phenotypes may reflect particular patho-
physiological mechanisms.51 For example, certain patients have
principally deafferentation with loss of sensory function, whereas
others have evidence of preserved small-fibre function and
associated hypersensitivity, a pattern termed the irritable
nociceptor.16,20 An aspiration is to use patient stratification in
regard to targeting therapy.2 Sensory phenotyping may aid in the
design of randomised controlled trials of analgesics, for instance,
by enrolling patients according to the sensory phenotype that
may be most responsive to a particular drug.9,41
In the Pain in Neuropathy Study (PiNS), we aimed to
characterise, in unprecedented depth, the somatosensory
phenotype of patients with DPN. Our objectives were (1) to
compare patients with and without NeuP to identify sensory
abnormalities that were specific to NeuP, (2) to compare some of
the existing commonly used screening tools for NeuP in these
populations, and (3) to relate sensory phenotype to measures of
DPN severity and HbA1c to investigate the relationship between
NeuP and the underlying disease process.
2. Material and methods
2.1. Study design and patients
The PiNS is an observational cross-sectional multicentre study
approved by the National Research Ethics Service of the United
Kingdom (No.: 10/H07056/35). Most of the study participants
were recruited fromprimary care practices in London andOxford.
Study participants were also recruited from diabetes clinics at
Chelsea and Westminster Hospital (London), Sheffield Teaching
Hospitals and Oxford University Teaching Hospitals; neurology
clinics at King’s College Hospital (London), and through
advertisements. All study participants signed written consent
before participating.
Patients with diabetes mellitus aged above 18 years with
diagnosed DPN, or patients with symptoms and signs suggestive
of DPN were included. Exclusion criteria were pregnancy,
coincident major psychiatric disorders, poor or no English
language skills, severe pain at recruitment from a cause other
than DPN (to prevent potential confounding influence on pain
reporting as well as psychological and quality-of-life reported
outcomes), patients with documented central nervous system
lesions, or patients with insufficient mental capacity to provide
informed consent or to complete questionnaires.
The sensory phenotyping paradigm was aligned with a pre-
vious study of HIV polyneuropathy.36 The study design consisted
of a single clinical assessment appointment with questionnaires
that were completed either before or after the appointment and
then returned to the study centre by post. During the clinical
assessment appointment, participants had detailed medical and
drug histories documented that included sex, age, ethnicity,
medical history, date of diabetes mellitus diagnosis, presence of
a family history of neuropathy, presence of other potential causes
of neuropathy (hypothyroidism, HIV, alcohol misuse, vitamin B12
deficiency, and neurotoxic drug exposure); smoking and alcohol
consumption were assessed using UK Department of Health
methodology.23 Basic clinical parameters were then measured
for each participant (weight, height, and lying/standing blood
pressures). Participants then underwent a structured neurolog-
ical examination, a detailed QST assessment, nerve conduction
studies, and skin biopsy. After the clinical assessment, the study
investigators collected further drug, laboratory, and clinical
investigation data from the clinical records. The data, where
available, included detailed drug histories, nerve conduction
study data, and the most recent routine haematological and
biochemical parameters.
2.2. Structured neurological examination
A comprehensive structured upper and lower limb neurological
examination was performed to detect clinical signs of a peripheral
neuropathy.27,34 The examination included assessment of
temperature, light touch and pinprick sensation, joint position
proprioception, vibration perception, deep-tendon reflexes,
muscle bulk, and motor power. Orthostatic hypotension, as
a marker of autonomic neuropathy, was assessed by measuring
lying and standing blood pressure in accordancewith established
protocols.14 Orthostatic hypotension was defined as either a 20
mm Hg reduction in systolic or a 10 mm Hg reduction in diastolic
blood pressure assessed two minutes after standing.
2.3. Nerve conduction tests
Nerve conduction tests were performed with an Advance system
(NeuroMetrix, Waltham, MA) and used conventional reusable
electrodes. Sural sensory and peroneal motor nerve conduction
studies were performed in one lower extremity. If both studies
were normal,11 no further tests were performed. If either test was
abnormal, additional nerve conductions were performed that
included ipsilateral tibial motor nerve; contralateral sural sensory
nerve, peroneal motor or tibial motor nerves; or ulnar sensory,
median sensory, and ulnar motor nerves in one upper extremity.
The minimum case definition criterion for electrodiagnostic confir-
mation of DPN was an abnormality of any attribute of nerve
conduction in 2 separate nerves, one of which was the sural nerve.
Variables such as skin temperature, age, height, sex, and weight
were measured and accounted for when interpreting nerve
conduction tests. Our protocol was in line with those recommended
by the American Academy of Neurology and American Association
of Electrodiagnostic Medicine.19 Nerve conduction tests were not
repeated if study participants had previous results.
2.4. Skin biopsy for intraepidermal nerve fibre
density assessment
The determination of intraepidermal nerve fibre density (IENFD)
from skin biopsy samples is a validated and sensitive diagnostic
tool for the assessment of small-fibre neuropathies, including
diabetic neuropathy.29 Punch biopsies of the skin were
performed immediately after the completion of QST. Skin
biopsies were not taken from participants on warfarin or those
who had other contraindications to skin biopsy. Biopsy samples
were taken in accordance with the consensus document
produced by the European Federation of Neurological
Societies/Peripheral Nerve Society Guideline on the utilisation of
skin biopsy samples in the diagnosis of peripheral neuropa-
thies.29 Subcutaneous anaesthesia was achieved with lidocaine
(1%, 1-1.2 mL) before the biopsy was taken under sterile
conditions. Skin biopsies were taken 10 cm proximal to the
lateral malleolus with a disposable 3-mm punch biopsy circular
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blade (Stiefel Laboratories Inc, GSK Plc, Brentford, United
Kingdom). The biopsy was fixed in fresh periodate-lysine-
paraformaldehyde (2%) for 12 to 24 hours. Tissue was then
washed in 0.1 M phosphate buffer and stored for 2 to 3 days in
15% sucrose in 0.1 M phosphate buffer. After embedding in O.C.
T. (Fisher Scientific UK Ltd, Loughborough, United Kingdom), the
tissue was snap-frozen and stored at 280˚C.
Sections with 50-mm thickness were cut on a cryostat, and
immunohistochemistry for protein gene product 9.5 was per-
formed on free-floating sections using the immunoperoxidase
method. Samples were selected at random. Staining was
performed on 24-well plates allowing reagents complete pene-
tration of floating samples. For the bright-field method, samples
were washed with TBS and placed on a 5% hydrogen peroxide
solution on ethanol, followed by blockade of nonspecific protein
binding with 4% normal donkey serum, 0.5% milk, and 0.1%
Triton X in TBS. Primary antibody rabbit anti–protein gene product
9.5 Ab (1:15,000; Ultraclone Ltd, Yarmouth, Isle of Wight, United
Kingdom) was incubated overnight at room temperature. After
rinsing the samples with TBS, secondary Biotinylated Goat Anti-
Rabbit IgG Antibody (1:400; Vector Laboratories, Burlingame,
CA) was used followed by addition of VECTASTAIN ABC Kit
(Vector Laboratories) for 1 hour. Samples were washed and
transferred to the DAB Peroxidase Substrate Kit, 3,39-diamino-
benzidine (Vector Laboratories) until a visible stain emerged.
Samples were rinsed with distilled water and progressively
dehydrated with ethanol. Samples were mounted using DPX
mounting media. Protein gene product 9.5-immunoreactive
nerve fibres crossing the basal membrane of the epidermis were
counted under a340 objective, and ameasurement of the length
of the sample was also obtained. The IENFD was assessed using
a double bright-field microscope at 340 magnification using
established counting rules and expressed as fibres per millimetre
of epidermal length. IENFD was considered abnormal if it was
below the fifth centile for age- and sex-matched healthy
controls.28
2.5. Quantitative sensory testing
Somatosensory phenotypes were determined according to
a previously published protocol of the German research network
of neuropathic pain (DFNS).38 The investigators (A.C.T., S.R.P.,
and J.D.R.) underwent a formal training in conducting the DFNS
QST protocol at Mannheim University using healthy volunteers.
Cold andwarm detection thresholds aswell as cold and heat pain
thresholds and thermal sensory limen (including paradoxical heat
sensations) were established using a Thermotest (Somedic,
Ho¨rby, Sweden). We also tested mechanical detection and pain
thresholds and mechanical pain sensitivity, allodynia, pressure
pain thresholds (PPTs), wind-up ratio (WUR), and vibration
detection thresholds. Participants were familiarized with the
testing procedure on the dorsum of the forearm before all
parameters were measured over the dorsum of both feet (S1
dermatome). Pressure pain thresholds were recorded over the
arch of the foot, and vibration detection thresholds were tested
over the medial malleolus.
Quantitative sensory testing data were entered into the data
analysis system Equista provided by the DFNS. Equista trans-
formed the raw QST data into z-scores thus normalising for age,
sex, and the body location of testing.31,39 Positive z-scores
denote gain of function, whereas negative z-scores denote loss of
function. The sample size was determined according to the warm
detection threshold data for patients with diabetes.40 This
calculation revealed that a minimum sample size of 34 was
required per group for a power of.0.8 (difference in means 2.0;
SD 4.3; a 5 0.05).
We calculated warm and cold sensibility indices to determine the
pain sensitivity range in which thermal sensations were felt.25 The
warm sensibility index (WSI) was defined as: (warm pain detection
threshold 2 warm threshold)/(warm pain detection threshold 2
reference temperature). The cold sensibility index (CSI) was defined
as: (cold pain detection threshold 2 cold threshold)/(cold pain
detection threshold2 reference temperature).
2.6. Neuropathy screening tools, symptom, and
function questionnaires
A set of questionnaires assessing the presence of pain, pain
intensity, pain distribution, and the psychological and functional
impact of pain were either completed before the appointment or
after the appointment and then returned to the study centre by
post. We briefly describe the tools used. Detailed descriptions of
the tools can be found in supplementary methods (available
online as Supplemental Digital Content at http://links.lww.com/
PAIN/A226).
Patients were asked to keep a pain intensity diary for 7 days,
recording pain at 9 AM and 9 PM daily on an 11-point scale, with
0 being no pain and 10 the worst pain imaginable. Study
participants also completed a body map highlighting the
distribution of any pain experienced. The surface area of NeuP
was calculated from the body areas highlighted on the bodymap.
Areas of pain were highlighted on a computer-generated image of
a standardised body map, and the surface area of NeuP was
subsequently quantified. The pain diary was used to assess the
presence and severity of painful diabetic neuropathy.
The Toronto Clinical Scoring System (TCSS)10 was used as
a screening tool for DPN and correlates with diabetic neuropathy
severity. The Douleur Neuropathique en 4 Questions (DN4)6 was
used as a screening tool for NeuP. The PainDETECT22 was used
as a self-administered screening tool for NeuP. The Brief Pain
Inventory (BPI)44 includes pain severity and pain interference
scores that were used to assess the severity any type of pain
(nonneuropathic and neuropathic) experienced and the impact of
the pain on activities of daily living. The Neuropathic Pain
Symptom Inventory (NPSI),7 a self-administered questionnaire,
was used to evaluate NeuP symptoms including evoked pain,
spontaneous pain, paroxysmal pain, and dysesthesias. The Pain
Catastrophizing Scale (PCS)35 was used to assess the cognitive
process by which pain is appraised. The Depression Anxiety
Positive Outlook instrument (DAPOS)37 was used to measure
mood and anxiety. The Pain Anxiety Symptom Scale 20 (PASS-
20)33 was used to assess pain-related anxiety. Survey of
Autonomic Symptoms (SAS)54 was used to measure the
presence and impact of autonomic symptoms. The Insomnia
Severity Index (ISI)3 was used to measure the study participant’s
perception, subjective symptoms, and the consequences of any
sleep disturbances. The Short-Form 36 of the MOS Outcomes
Study (SF-36)52 was used for the assessment of health-related
quality of life.
2.7. Definition of painful diabetic neuropathy
All study participants enrolled had diabetes mellitus. Study
participants were screened for a “possible” clinical neuropathy
defined as a combination of symptoms or signs of neuropathy
including any one or more of the following: neuropathic
symptoms (decreased sensation, positive sensory symptoms,
eg, burning, aching pain) mainly in the toes, feet, or legs;
1134 A.C. Themistocleous et al.·157 (2016) 1132–1145 PAIN®
decreased distal sensation; decreased/absent ankle reflexes, and
the DPN was then confirmed by abnormalities on either the nerve
conduction studies or IENFD46 (Figure 1). Only study participants
with a confirmed DPN proceeded to NeuP subtyping.
The presence of chronic NeuP caused by peripheral DPN was
determined at the time of the clinical assessment and was in line
with the IASP definition of NeuP, ie, “pain caused by a lesion or
disease of the somatosensory system” (Figure 1) and the IASP/
NeuPSIG grading system was used.48
The assessment of each study participant therefore satisfied
the following criteria:
1. Pain with a distinct neuroanatomically plausible distribu-
tion, ie, pain symmetrically distributed in the extremi-
ties—completion of body map and clinical history.
2. A history suggestive of a relevant lesion or disease affecting
the peripheral or central somatosensory system—diag-
nosis of diabetes mellitus and a history of neuropathic
symptoms including decreased sensation, positive sen-
sory symptoms, eg, burning, aching painmainly in the toes,
feet, or legs
3. Demonstration of the distinct neuroanatomically plausible
distribution by at least 1 confirmatory test—presence of
clinical signs of peripheral neuropathy, ie, decreased distal
sensation or decreased/absent ankle reflexes
4. Demonstration of the relevant lesion or disease by at least 1
confirmatory test—abnormality on either the nerve con-
duction tests or IENFD.
Only study participants with chronic NeuP present for at least 3
months were included in the NeuP groups. Study participants
with non-NeuP in the extremities, such asmusculoskeletal pain of
the ankle, were included in the no NeuP group. The severity of
NeuP was calculated as the mean of the pain scores obtained
from the 7-day pain intensity diary. The study participants were
thereafter allocated into 3 groups based on the mean pain
intensity score: 0: no NeuP, 0.1 to 3.9: mild NeuP, and 4 to 10:
moderate/severe NeuP.18
2.8. Statistical analysis
SPSS Statistics Version 21 (IBM) and GraphPad Prism were
used for statistical analysis. The QST z-scores were compared
across the 3 groups with 1-way ANOVA (LSD post hoc test), or
between 2 groups with unpaired t-tests. The QST z-score data
were expressed as mean6 95% CI. All other data were tested
for normality with the D’Agostino-Pearson normality test and
by visual inspection of their distribution. All other data were not
normally distributed and reported as median with interquartile
range (IQR). Data were compared across the 3 groups with the
Figure 1. Flow diagram of study participant recruitment and the criteria used to subdivide the study participants into the different subgroups.
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Kruskal–Wallis test (Dunn pots hoc test), or between 2 groups
with the Mann–Whitney U test. Spearman correlation analyses
were performed to explore associations between histological
parameters, QST findings, neurophysiological data, and
symptom and functional outcomes. Categorical data were




A total of 209 patients were assessed. We recruited 191 study
participants with DPN (9 study participants were excluded
because they did not complete their 7-day pain intensity
dairies). A smaller group, as a result of targeted recruitment for
DPN, of 18 study participants were found not to have DPN
according to our criteria. All study participants were clinically
assessed by one of the study investigators (A.C.T., J.D.R.,
and P.R.S.). Study participants with DPN were divided into
groups according to the severity of their NeuP: 80 participants
had no NeuP, 41 had mild NeuP, and 70 hadmoderate/severe
NeuP.
3.2. Demographics and pharmacotherapy use
All study participants had a diagnosis of diabetic mellitus.
Most of the study participants were aged above 60 years and
were white, and two thirds of the participants were men
(Table 1). There were no significant differences between the
different groups in terms of sex, ethnicity, body mass index,
waist–hip circumference. Most of the study participants
(91.1%) had type 2 diabetes mellitus, in line with population
prevalence. Study participants across the 3 groups were
diagnosed with diabetes for a similar duration. There were 17
study participants who had type 1 diabetes mellitus and 12
participants with DPN NeuP. It is therefore not possible to
comment on variations of somatosensory phenotype between
type 1 and type 2 diabetic participants, as the size of the type 1
cohort is too small to make a meaningful comparison.
However, a significant finding is that the median (IQR) duration
of diabetic treatment was different between the 2 groups:
31.8 (28.4) years for type 1 diabetes mellitus and 13.3 (12.4)
years for type 2 diabetes mellitus (Mann–Whitney U test, P ,
0.01). The participants with moderate/severe NeuP were
slightly younger and had poorer diabetic control (demon-
strated by a significantly higher HbA1c, results available in 199
(95%) of study participants) compared with those with DPN
with no NeuP (Table 1). HbA1c correlated with NeuP severity
(r 5 0.21, P , 0.01), and although the association is not
strong, it is statistically significant.
There was increased reported analgesic use in study
participants with NeuP (Table 2). Those with the moderate/
severe NeuP reported greater use of the serotonin–
norepinephrine reuptake inhibitors (SNRIs) duloxetine and
pregabalin. Although the mild NeuP reported greater use of
analgesics, the choice of analgesic did not differ
compared with the study participants with no NeuP. Study
participants with DPN with no NeuP were prescribed
antidepressants or antiepileptics classically used for NeuP.
The reasons for the use of amitriptyline were either as a night
time sedative for sleeping difficulties or for pain (not
necessarily neuropathic) that was unrelated to their DPN.
Gabapentinoids were prescribed for suspected NeuP un-
related to their DPN, and it should be noted that these patients
did not have a history of painful DPN that was relieved
completely by their treatment. We have included a summary of
all reported drug use (Supplementary Table 1, available online
as Supplemental Digital Content at http://links.lww.com/
PAIN/A226).
3.3. Pain questionnaires, pain diary, and body maps
Study participants with painful DPN scored higher on
screening tools, the DN4 and painDETECT, designed to detect
pain with neuropathic characteristics (Table 3). Our gold
standard for the definition of NeuP was the IASP/NeuPSIG
Table 1
Summary of key demographic details and blood results.
No NeuP Mild NeuP Moderate/severe NeuP P
Number of participants 80 41 70
Age, y 68.6 (61.1-73.4) 68.5 (61.2-73.3) 64.6 (54-70.5) 0.03
Male 53 (66.3%) 33 (80.5%) 43 (61.4%) 0.11
Ethnicity 0.14
White European 78 (97.4%) 41 (100%) 61 (87.1%)
African origin 1 (1.3%) 0 (0%) 4 (5.7%)
Asian 1 (1.3%) 0 (0%) 1 (1.4%)
Mixed ethnicity 0 (0%) 0 (0%) 2 (2.9%)
Other 0 (0%) 0 (0%) 2 (2.9%)
HbA1c, % [mmol/mol] 7.3 (6.6-8.1) [56 (49-65)] 7.5 (6.8-8.9) [59 (51-74)] 7.8 (6.9-8.9)* [62 (51-72)] 0.05
Type 2 diabetes 75 (93.8%) 37 (90.2%) 62 (88.6%) 0.53
Duration of diabetes, y 14.1 (9.8-21.8) 13.55 (8.0-23.2) 14.2 (7.6-21) 0.74
Standing BP 143/80 (619/12) 143/77 (620/11) 137/76 (618/14) 0.14
Lying BP 144/78 (618/10) 146/77 (617/11) 145/79 (616/11) 0.74
Orthostatic hypotension 10 (13%) 8 (20%) 15 (22%) 0.31
BMI, kg/m2 30.1 (26.2-35) 31.1 (27.1-37.1) 31.1 (26.7-35.9) 0.82
Waist–hip circumference ratio 0.96 (0.91-1.04) 0.96 (0.90-1.04) 0.99 (0.92-1.04) 0.21
Data shown as median (interquartile range) and analysed by the Kruskal–Wallis, Dunn multiple comparison test. Categorical data were analysed by the x2 test of association, and values and percentages are shown.
Symbols reflect the differences between the respective groups.
* P , 0.05 between no neuropathic pain (NeuP) and moderate/severe NeuP.
BMI, body mass index; BP, blood pressure.
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grading system.48 Using this as a reference, the sensitivity of
DN4 and painDETECT was 88.3% and 61.3%, respectively,
and the specificity of DN4 and painDETECT was 92.5% and
91.7%, respectively. The DN4 and painDETECT, correlated
well with themean score obtained from the 7-day pain intensity
diary (Fig. 2). Some study participants with DPN and no NeuP
still experienced pain in their feet or legs, such as musculo-
skeletal pain of the ankle or leg cramps, that was unrelated to
their DPN. The DN4 and painDETECT quantified the NeuP
characteristics of this nonneuropathic lower limb pain
(Table 3)
A similar proportion of study participants with mild NeuP and
moderate/severe NeuP reported NeuP in their hands; however,
those with moderate/severe NeuP experienced NeuP over
a greater surface area of their hands (P, 0.05,Mann–Whitney U
test) (Fig. 3C). There were no differences in either the frequency
or surface area distribution of NeuP over the leg between study
participants with mild NeuP and moderate/severe NeuP (Fig.
3C). Using the NPSI, study participants with moderate/severe
NeuP reported greater severity of symptoms across all
parameters of the NPSI compared with those with mild NeuP
(Table 3).
Study participants in all groups did report pain of non-
neuropathic origin, and the distribution of the pain is shown as
blue areas in Figure 3C. In the majority of cases, the non-NeuP
related to nonspecific lower back pain and musculoskeletal pain
of the hip, knee, or ankle. The high frequency of such non-NeuP
highlights the importance of detailed pain assessment in clinical
trials of analgesic agents designed to ameliorate NeuP in diabetes
mellitus.
Table 2
Summary of analgesic use.
No NeuP Mild NeuP Moderate/severe NeuP P
Number of participants 80 41 70
Analgesic use
Participants reported analgesic drug use 24 (30.0%) 23 (56.1%)* 55 (78.6%)†‡ <0.01
Paracetamol 12 (50.0%) 8 (34.8%) 25 (45.5%) 0.55




10 (41.7%) 11 (47.8%) 13 (23.6%) 0.07
SNRI (duloxetine) 1 (4.2%) 1 (4.3%) 17 (30.9%)†‡ <0.01
Gabapentinoids
Gabapentin 2 (8.3%) 5 (21.7%) 13 (23.6%) 0.28
Pregabalin 2 (8.3%) 0 (0%) 18 (32.7%)§‖ <0.01
Topical lidocaine patches 0 (0%) 0 (0%) 3 (5.7%) 0.27
Tramadol 2 (8.3%) 1 (4.3%) 12 (21.8%) 0.08
Opioids
Weak (codeine) 8 (33.3%) 6 (26.1%) 18 (32.7%) 0.82
Strong (fentanyl patches, oral morphine) 1 (4.2%) 0 (0%) 6 (10.9%) 0.39
Data shown as values and percentages and analysed by x2 test of association.
Symbols reflect the differences between the respective groups.
* P , 0.01 between no NeuP and mild NeuP.
† P , 0.01 between no neuropathic pain (NeuP) and moderate/severe NeuP.
‡ P , 0.05 between mild NeuP and moderate/severe NeuP.
§ P , 0.05 between no neuropathic pain (NeuP) and moderate/severe NeuP.
‖ P , 0.01 between mild NeuP and moderate/severe NeuP.
NSAIDS, nonsteroidal anti-inflammatory drugs; SNRI, serotonin–norepinephrine reuptake inhibitor.
Table 3
Summary of neuropathic pain (NeuP) screening scores.
No NeuP Mild NeuP Moderate/severe NeuP P
API NA 2.1 (1.4-3.4) 6.5 (5.2-7.6)
DN4 1.5 (0-3) 5 (4-6.5)* 6 (5-7)† ,0.01
painDETECT 2 (0-6) 12 (7-17)* 18 (11-23)†‡ ,0.01
BPI pain severity 1.3 (0-3.2) 2.8 (2-3.8)§ 6 (4.5-7.3)†‖ ,0.01
NPSI total NA 1.6 (1.0-2.5) 4.0 (2.5-9.4) ,0.01
NPSI deep spontaneous pain NA 0 (0-1.5) 2.5 (0-5) ,0.01
NPSI superficial spontaneous pain NA 1 (0-3.5) 7 (3-8) ,0.01
NPSI evoked spontaneous pain NA 0.7 (0-1.7) 2.3 (0-5.4) ,0.01
NPSI paraesthesiae NA 2 (1-4.3) 5.8 (2.4-8) ,0.01
NPSI paroxysmal pain NA 2 (0-4) 4.3 (1-7.5) ,0.01
Data shown as median (interquartile range) and analysed by the Kruskal–Wallis, Dunn multiple comparison test.
Symbols reflect the differences between the respective groups.
* P , 0.01 between no NeuP and mild NeuP.
† P , 0.01 between no NeuP and moderate/severe NeuP.
‡ P , 0.05 between mild NeuP and moderate/severe NeuP.
§ P , 0.05 between no NeuP and mild NeuP.
‖ P , 0.01 between mild NeuP and moderate/severe NeuP.
API, 7-day pain diary; BPI, Brief Pain Inventory; NPSI, Neuropathic Pain Symptom Inventory.
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3.4. Structured neurological examination, nerve conduction
studies, and intraepidermal nerve fibre density
The TCSS total scorewas significantly higher in study participants
with NeuP compared with no NeuP (Fig. 3A and Supplementary
Table, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A226). The study participants with
a NeuP reported more frequent sensory symptoms such as
paraesthesiae and numbness, which was also of greater
intensity. Patients with painful neuropathy also had amore severe
DPN on clinical examination. There was greater proximal spread
of clinical signs as evidenced by a higher Medical Research
Council (MRC) sensory sum score (Supplementary Table 2,
available online as Supplemental Digital Content at http://links.
lww.com/PAIN/A226). The TCSS and MRC sensory sum scores
correlatedwith NeuP intensity (Fig. 4). The nerve conduction studies
(Supplementary Table 2, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A226) and IENFD (Fig. 3 and
Supplementary Table 2, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A226) did not discriminate
between study participants with and without a NeuP. Sural sensory
nerve responses were absent in 54% of study participants with
diabetic neuropathy; and in study participants with preserved
responses, the amplitudes were reduced with slowing of conduc-
tion. Peroneal motor response was absent in 23% of study
participants with diabetic neuropathy; and in study participants with
preserved responses, the amplitudes were reduced with slowing.
There were no electrophysiological differences between participants
with and without NeuP (Supplementary Table 2, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/A226).
The IENFD measured in a biopsy taken at 10 cm above the lateral
malleolus was markedly reduced among all study participants with
a peripheral neuropathy and did not correlate with the mean pain
scores andwasnot significantly different betweengroups (Fig. 3 and
Supplementary Table 2, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A226).
3.5. Quantitative sensory testing
Quantitative sensory testing is a means of assessing sensory
phenotype, and differences in QST parameters may give insight into
pathophysiological mechanisms. All study participants underwent
QST of the feet using the protocol developed by the DFNS.
The data for thermal QST parameters for study participants
with DPN are summarised in Figure 5A. Themean z-scores for all
thermal parameters, apart from the cold detection threshold in
participants with moderate/severe NeuP, fell within the normative
range of the DFNS healthy control data, although data from
individual participants did fall outside the normative range.
Between-group comparisons revealed significant differences in
the loss-of-function direction, and the shift towards thermal
hypoaesthesia was greatest in the study participants with
moderate/severe NeuP. The only thermal parameter that showed
no differences across all 3 groups was cold pain thresholds as
most study participants reached the cut-off temperature in-
dicating a “flooring effect”. The mean z-scores for all thermal
parameters for the study participants without DPN all fell within
the normative range and were significantly higher across
parameters when compared with study participants with DPN
(Supplementary Figure 1, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A226).
The WSI and CSI are measures for the range of thermal
sensitivity. Therewere clear reductions in theWSI andCSI between
study participants with no DPN and those with DPN (Supplemen-
tary Figure 2, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A226). However, WSI did not discrim-
inate between patients with and without NeuP. In contrast, CSI
showed small differences between the study participants with
moderate/severe NeuP and the study participants with no or mild
NeuP (Supplementary Figure 2, available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A226).
The data for mechanical QST parameters for participants with
DPN are summarised in Figure 5B. The mean z-score for
mechanical detection threshold (MDT) in study participants with
moderate/severe painful diabetic neuropathy was reduced (ie,
indicating hyposensitivity) when comparedwith the DFNS healthy
control cohort and was significantly lower than the study
participants with no NeuP. Mean z-score values for the VDT
when compared with the DFNS normative data revealed a loss of
function for the VDTwith no difference across the 3 groups. Mean
z-scores of all other mechanical parameters fell within the
normative range of the DFNS healthy control data. The mean z-
scores of the mechanical parameters for the study participants
without DPN all fell within the normative range, and apart from
WUR and PPT, were significantly higher across parameters when
compared with study participants with DPN (Supplementary
Figure 1, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A226).
The frequency of abnormal QST values outside 2 SD of themean
for DFNS healthy control data is shown in Figure 5C. The overall
pattern for thermal parameters is similar to the mean z-scores, with
Figure 2. Scatter plot of (A) DN4 scores, (B) painDETECT scores, against 7-
day pain intensity diary mean. All screening scores were highly correlated with
the 7-day pain dairy mean (Spearman correlation).
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the highest frequency of loss of function in the study participants
associated with moderate/severe painful diabetic neuropathy. For
the mechanical parameters, all 3 groups showed a high frequency
of loss of function across VDT, mechanical pain threshold, and
MDT. Significant difference was observed for MDT, with a higher
percentage of study participants showing a loss of function with
moderate/severe NeuP compared with participants with no NeuP.
Overall, a smaller frequency of study participants showed loss of
function formechanical pain sensitivity,withmore study participants
showing a loss of function with moderate/severe NeuP compared
with no NeuP. Statistically significant gain of function was not
observed across the thermal and mechanical parameters, apart
from dynamic mechanical allodynia.
3.6. Allodynia, paradoxical heat sensation, and irritable
nociceptor subtype
The presence of dynamic brush-evoked allodynia would suggest
aberrant central processing contributing to NeuP in these
patients. This was an example of a QST finding that was specific
to NeuP as it was only observed in participants with NeuP,
Figure 3C—7 (17%) in mild NeuP and 10 (14%)moderate/severe
Figure 3. (A) Scatter plot and median (interquartile range [IQR]) of Toronto Clinical Scoring System (TCSS) scores for study participants with no peripheral diabetic
neuropathy, and diabetic neuropathy with no neuropathic pain (NeuP), mild NeuP, moderate/severe NeuP. Kruskal–Wallis, Dunn multiple comparison test: **P,
0.01. (B) Scatter plot andmedian (IQR) of intraepidermal nerve fibre density (IENFD) from the distal leg for study participants with no peripheral diabetic neuropathy,
and diabetic neuropathy with no NeuP, mild NeuP, moderate/severe NeuP. Intraepidermal nerve fibre densities were determined for 182 (87%) study participants.
Kruskal–Wallis, Dunn multiple comparison test: **P, 0.01. (C) Heat maps obtained from the 7-day pain diary demonstrating the areas of NeuP (in red) and non-
NeuP (in blue) within the study participants with diabetic neuropathy and no NeuP, mild NeuP, and moderate/severe NeuP.
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NeuP. The participants with allodynia did not differ from those in
whom allodynia was not elicited across demographic data,
clinical measurements, nerve conduction studies, IEFND and
psychological problems, sleep disturbance, and health-related
quality of life. A significantly higher number of study participants
reported evoked pain, ie, allodynia, 39.8% on the NPSI than the
15% of study participants with NeuP who were found to have
clinical evidence of dynamic brush-evoked allodynia (Fig. 6).
Paradoxical heat refers to the perception of heat in response to
cooling and has been reported across a diverse range of
peripheral neuropathies.32 Paradoxical heat sensations were
observed across all groups with DPN, and the proportions were
not statistically different, 41.3%without and with 40%with NeuP.
Unlike allodynia, it was not discriminatory between patients with
NeuP and those without NeuP. It can therefore not be seen as
a “positive” sensory sign but likely represents loss of function. We
assessed the presence of paradoxical heat sensation in only
those who retained thermal perception; therefore, when com-
pared with those who did not report paradoxical heat sensations,
they retained thermal perception and hadmilder neuropathy. The
concept of the “irritable nociceptor” is of a sensory phenotype
with preserved small-fibre function (cold, warm, and pinprick
sensitivity) together with hyperalgesia. Applying preexisting
criteria16 for the definition of the irritable nociceptor, we found
this to be a rare subtype in DPN. The irritable nociceptor subtype
was observed in only 4.9% of participants with mild NeuP, and
7.1% of participants with moderate/severe NeuP. The partic-
ipants with irritable nociceptor subtype did not differ from those
without the irritable nociceptor subtype across demographic
data, clinical measurements, NCS, IENFD, psychological mor-
bidity, sleep disturbance, and health-related quality of life.
3.7. The relationship between clinical examination,
quantitative sensory testing, and intraepidermal nerve
fibre density
Quantitative sensory testing thermal and mechanical parameters,
apart from WUR, correlated well with the clinical scores when
considering all the study participants, ie, including those with and
without DPN (Table 4). The clinical scores, TCSS andMRC sensory
sum score, correlated negatively with QST z-scores. Therefore, the
higher the clinical scores, ie, more severe the DPN, the greater the
loss of sensation on QST parameters. The IENFD positively
correlated with QST thermal andmechanical parameters, apart from
WUR, among all the study participants, ie, including those with and
without DPN. Therefore, preserved epidermal innervation correlates
with preserved sensory function across the QST parameters.
3.8. Psychological well-being and quality-of-life measures
Study participants with moderate/severe NeuP reported statis-
tically significant higher scores for the ONLS, PCS, DAPOS,
PASS-20, ISI, BPI Pain interference, and SF-36 when compared
with study participants with no NeuP or mild NeuP (Table 5).
Therefore, among the study participants with moderate/severe
NeuP, the rates of physical disability, pain catastrophization,
depression, anxiety, clinical insomnia, and poorer quality of life
were significantly higher.
4. Discussion
We have undertaken detailed sensory phenotyping using patient-
reported pain descriptors, sensory examination, andQST in a large
cohort of patients with diabetic neuropathy, predominantly in those
with type 2 diabetes mellitus. This sensory phenotype has then
been compared in patients with and without NeuP and related to
detailed assessment of neuropathy severity. Key findings are that
the DN4 questionnaire performed extremely well as a screening
instrument for NeuP in this population, the presence (and severity)
of NeuP was associated with more advanced DPN and higher
HbA1c, and QST revealed hyposensitivity across a range of small-
fibre and large-fibre mediated sensory modalities, and this sensory
loss was most marked in patients with moderate/severe NeuP
compared with patients with mild or no NeuP. Only a minority of
patients had sensory gain signs, and very few patients with NeuP
would be classified in the “irritable nociceptor” group.
Our diagnosis of DPN and NeuP was based on a combination
of clinical probability followed by confirmatory investigations. We
have used the NeuPSIG grading system48 as a gold standard to
define patients with chronic NeuP. Such pain lasted longer than 3
months of duration, in a neuroanatomically plausible distribution
(symmetrical pain in the extremities), accompanied by a history of
a disorder affecting the somatosensory nervous system (con-
firmed DPN), associated with abnormal sensory signs and
a confirmatory test showing a lesion of the somatosensory
nervous system (reduced IENFD or abnormal nerve conduction
studies). Compared with this gold standard, the patient-reported
symptom-based approach of the DN4 questionnaire performed
extremely well in identifying patients with NeuP and performed
better than another commonly used screening tool for NeuP, the
Figure 4. Scatter plot of (A) Toronto Clinical Scoring System (TCSS), and (B)
MRC sensory sum score scores, against the 7-day pain intensity diary mean
showing a correlation of clinical neuropathy severity and neuropathic pain
intensity (Spearman correlations).
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Figure 5. (A) Scatter plot andmean6 95%CI of z-scores for thermal quantitative sensory testing (QST) parameters in study participants with no neuropathic pain
(NeuP), mild NeuP, andmoderate/severe NeuP. One-way analysis of variance (ANOVA), least significant difference (LSD) post hoc test: *P, 0.05; **P, 0.01. (B)
Scatter plot andmean6 95%confidence interval of z-scores formechanical QSTparameters in study participantswith noNeuP,mild NeuP, andmoderate/severe
NeuP. One-way ANOVA, LSD post hoc test: **P, 0.01. (C) Loss and gain of sensory function. Comparison of study participants with no NeuP, mild NeuP, and
moderate/severe NeuPwho haveQST values outside the 95%confidence interval of theGerman research network of neuropathic pain reference database. The y-
axis shows the percentage of patients in each group with ‘gain’ of sensory function plotted upwards and “loss” of sensory function plotted downwards. Data
analysed with x2 test of association: †P, 0.05, ††P, 0.01 between no NeuP and moderate/severe NeuP, ##P, 0.01 between no NeuP and mild NeuP, ‡P,
0.05 between mild NeuP and moderate/severe NeuP. CDT, cold detection threshold; CPT, cold pain threshold; HPT, heat pain threshold; MDT, mechanical
detection threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold; PPT, pressure pain threshold; TSL, thermal sensory limen; VDT, vibration
detection threshold; WDT, warm detection threshold; WUR, wind-up ratio.
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PainDETECT. One previous study has studied the DN4 in DPN43;
however, there has never been a direct comparison between
these 2 questionnaires in this population.
Patients with NeuP were grouped into mild (mean pain numerical
rating scale.0 and,4) andmoderate/severe (mean pain numerical
rating scale $4). Patients with moderate/severe NeuP had greater
spatial distribution of pain than those with mild NeuP. The use of
analgesics paralleled the severity of NeuP with greater use of
pregabalin and duloxetine in the moderate/severe group (reassur-
ingly as these are drugs that are recommended for use in the
NeuP).12,21 Study participants with more severe NeuP reported
higher scores for anxiety, depression, poorer overall health, and
poorer quality of sleep compared with the study participants with no
NeuP and mild NeuP. It is unclear from our study whether these
comorbidities arepredisposing factors or complicationsof theNeuP.
The DFNS QST protocol has been increasingly used to
categorise the somatosensory profile of patients with NeuP in
a standardised manner. The PiNS is the first study to adopt the
DFNS protocol to specifically assess DPN, and importantly, we
have compared the sensory profile of subjects with and without
NeuP. In our cohort, the QST pattern of diabetic neuropathy was
consistent with loss of function in sensory modalities mediated by
both large and small sensory fibres. Furthermore, the study
participants with moderate/severe NeuP demonstrated the
greatest loss of function compared with the study participants
with mild NeuP or no NeuP. Diabetic NeuP would therefore be
predominantly classified under the “deafferentation” phenotype.
Interestingly, PPTs, as a measure of deep structure nociceptive
innervation, were not impaired in DPN and did not correlate with
NeuP suggesting that the deeper pain fibres are relatively intact.
Two broad sensory profiles that have emerged in the literature
have been termed the “irritable nociceptor” profile with preserved
small-fibre function (cold, warm, and pinprick sensitivity) together
with hyperalgesia and a “deafferentation” profile that is dominated
by sensory loss. Because very few DPN subjects have preserved
small-fibre function (compared with postherpetic neuralgia), very
few subjects would be classified within the “irritable nociceptor”
group in our cohort. Somepatients did however demonstrate signs
of sensorygain (often in combinationwith hyposensitivity). Dynamic
mechanical (brush-evoked) allodynia was the only evoked “gain of
function” parameter that discriminated between study participants
being present in 15% of DPN subjects with NeuP and absent from
those without NeuP. The presence of dynamic brush-evoked
allodynia would suggest aberrant central processing of sensory
inputs in these patients. We could not find any demographic or
clinical parameters that were specific to patients with brush-
evoked allodynia (for instance, there was no evidence that these
patients had less denervation)49; however, we were limited by the
relatively small size of this group. The discrepancy between
reported brush-evoked allodynia and clinical evidence of allodynia
is an interesting paradox that will not be easily answered. Most of
the study participants report allodynia in the evening, whereas we
examined the study participants during the day. However, there is
no evidence that allodynia varies during the day. There were
a significant number of study participants who exhibited allodynia
on clinical examination but did not report it, and questionnaires
would not capture this group of patients. Paradoxical heat
sensation (in which a cooling stimulus is perceived as being hot)
was relatively common in all DPN groups but did not differ for those
with and without NeuP, and this sign is probably as much
a “negative” as a “positive” sensory sign.
A previous article studying peripheral neuropathy of multiple
aetiologies also described a “deafferentation phenotype” in
most of the subjects.32 Sensory profiling of NeuP has
demonstrated distinct groups of patients with particular
patterns of sensory dysfunction that can be seen across
different aetiologies of NeuP. That is not to say however that
sensory profile does not differ depending on aetiology. In
contrast to DPN, patients with HIV-associated polyneurop-
athy, phenotyped using a protocol very similar to the PiNS, do
not exhibit dynamic mechanical allodynia and do exhibit an
increase in PPTs.36 Therefore, although HIV and diabetic
neuropathy both fall under the “deafferentation” profile, there
are clear differences between the different diseases.
Many studies have recorded assessment of NeuP in DPN,
but there are limited studies on the relationship between NeuP
Figure 6. Venn diagram demonstrating the number of participants with brush-
evoked allodynia reported only on questionnaires, dynamic mechanical
allodynia only on examination, participants with both reported allodynia and
allodynia on examination.
Table 4
Summary of correlations between quantitative sensory testing z-scores, and IENFD and clinical scores.
WDT CDT TSL CPT HPT MDT VDT MPT MPS WUR PPT
IENFD (fibres/mm) 0.40* 0.39* 0.35* 0.39* 0.23* 0.31* 0.35* 0.50* 0.54* 20.02 0.29*
MRC sensory sum score 20.49* 20.46* 20.47* 20.39* 20.46* 20.75* 20.61* 20.61* 20.45* 0.10 20.30*
TCSS total score 20.39* 20.40* 20.39* 20.30* 20.44* 20.63* 20.54* 20.37* 20.26* 0.10 20.17†
TCSS examination subscore 20.34* 20.42* 20.37* 20.35* 20.40* 20.60* 20.55* 20.38* 20.24 * 0.02 20.19*
Symbols reflect the significant differences between the respective groups.
Spearman correlation.
* P , 0.01.
† P , 0.05.
CDT, cold detection threshold; CPT, cold pain threshold; HPT, heat pain threshold; IENFD, intraepidermal nerve fibre density; MDT, mechanical detection threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain
threshold; PPT, pressure pain threshold; TCSS, Toronto Clinical Scoring System; TSL, thermal sensory limen; VDT, vibration detection threshold; WDT, warm detection threshold; WUR, wind-up ratio.
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and DPN severity and none in a cohort of this size. Using 2
clinical measures of neuropathy severity, TCSS and MRC
sensory sum scores were both higher in themild andmoderate/
severe NeuP groups and correlated with the severity of the
NeuP. The clinical scores were consistent with the greater
sensory loss in these groups revealed by QST. Therefore, DPN
severity correlates with NeuP consistent with other NeuP
conditions in which the more severe the injury to the
somatosensory system, the higher the likelihood of NeuP.
The IENFD is known to be reduced in DPN40 and was used as
a measure of loss of small fibres from the skin. We did not find
a correlation between IENFD and the severity of NeuP in our
cohort. Published studies on this point have been conflicting
with some groups reporting an inverse correlation between
IENFD and pain in DPN42 and others reporting no significant
relationship.15 It is something of a paradox that on using QST to
assess the functional integrity of small fibres, we saw greater
hyposensitivity in small-fibre modalities in the DPN inversely
correlating with NeuP; however, the measure of structural
integrity of small fibres did not differ. The most likely reason for
this is the flooring effect of IENFD, which was measured at
a distal site and was found to be markedly reduced both in
NeuP and no NeuP groups.
Thepresenceand severity ofNeuPcorrelateswith poorer diabetic
control in our patient cohort as reflected by higher HbA1c in the
NeuP group. It has long been established that poorer diabetic
control is a strong predictor for the development of diabetic
neuropathy, and a number of putative mechanisms have been
shown to contribute to hyperglycaemic induced nerve injury.12,13
The higher HbA1c in themoderate/severe NeuP group is consistent
with the more severe DPN in this cohort. Interestingly, metabolites
such as methylglyoxal produced as a consequence of hyper-
glycaemia can lead posttranslational modifications of ion channels
such as Nav1.85 directly resulting in hyperexcitability and NeuP.
Our findings have implications for the conduct of clinical trials of
analgesic agents for the treatment of NeuP in DPN. The DN4 is an
effective screening tool for NeuP in DPN. Many patients with DPN
have pain of nonneuropathic origin (for instance musculoskeletal
pain). This non-NeuP needs to be considered, and particular
attention should be paid to the location of the pain and exactly
what pain is being rated by patients. Distinct patterns of sensory
dysfunction are noted on QST, although the most common
finding is hyposensitivity to sensory stimuli. A minority of patients
did show sensory gain signs; however, the term “irritable
nociceptor” could only be applied to 6.3% of painful DPN. Given
the rarity of this “irritable nociceptor” group, it is unlikely to be
helpful in stratifying patients with painful DPN, in contrast to some
recent clinical trials in peripheral neuropathy of diverse causes.16
In summary, the PiNS has provided evidence in a well-
characterised DPN cohort that NeuP is related to neuropathy
severity. The sensory profile of patients with DPN with NeuP was
distinct from those patients without NeuP showing greater
hyposensitivity to sensory stimuli across a range of sensory
modalities. The sensory profile was not uniform in the NeuP
group, and an appreciable minority of patients also demonstrated
positive sensory signs such as dynamic allodynia; however, very
few patients would meet the criteria for the “irritable nociceptor”
group. This study provides us with a firm basis on which to
Table 5
Summary of scores for quality life measures, depression, anxiety, insomnia, and autonomic symptom abnormalities.
No NeuP Mild NeuP Moderate/severe NeuP P
ONLS 1 (0-2) 2 (0-3) 3 (1-4)*† ,0.01
BPI pain interference 0.7 (0-2.9) 2.1 (1.1-3.3) 5.5 (4-7.8)*‡ ,0.01
PCS rumination 2 (0-7) 3 (1-7) 8 (4-13)*‡ ,0.01
PCS magnification 1 (0-3) 2 (0.5-4) 4 (2-8)*‡ ,0.01
PCS helplessness 2 (0-7) 3 (1-5.5) 11 (6-16)*‡ ,0.01
PCS total 6 (0-16) 8 (5-14.5) 24 (11.3-38.8)*‡ ,0.01
DAPOS depression 6 (5-9.5) 6 (5-9) 8 (5-15)*† ,0.01
DAPOS anxiety 3 (3-4) 3 (3-6) 5 (3-8)*† ,0.01
DAPOS positive outlook 11.5 (9-14) 11 (9.5-13) 10 (7-12)*† ,0.01
PASS cognitive 3 (0-6) 5 (2-8.5) 11.5 (6-19.3)*‡ ,0.01
PASS escape–avoidance 3 (0-6) 5 (2-9.5) 10 (3.5-14.5)*‡ ,0.01
PASS fear 0 (0-2) 2 (0-5.5) 6 (1.8-14.3)*‡ ,0.01
PASS physiological anxiety 0 (0-1.8) 0 (0-4) 3 (0-9)*‡ ,0.01
PASS total 6 (0-16) 16 (6.5-24)§ 32 (15.5-55.5)*‡ ,0.01
SAS symptom score 3 (2-4) 3 (2-5) 5 (3-7)*† ,0.01
SAS total impact score 6.5 (3-10) 9 (5-13.5) 12 (7-19) ,0.01
ISI total score 7 (1.3-11.8) 8 (4-12.3) 16 (9-22)*† ,0.01
Clinical insomnia 12 (16.7%) 7 (18.4%) 32 (54.2%)*‡ ,0.01
SF-36 physical functioning 60 (40-80) 60 (30-85) 25 (10-55)*‡ ,0.01
SF-36 role physical 75 (25-100) 50 (0-100) 0 (0-50)*† ,0.01
SF-36 bodily pain 64 (51-84) 52 (41-62) 22 (21.5-41)*‡ ,0.01
SF-36 general health 50 (35-65.8) 55 (35-67) 30 (15-45)*‡ ,0.01
SF-36 vitality 55 (40-70) 50 (30-65) 40 (25-50)* ,0.01
SF-36 social functioning 100 (75-100) 87.5 (62.5-100) 37.5 (25-62.5)*‡ ,0.01
SF-36 role emotional 100 (67-100) 100 (33-100) 33 (0-100)*‡ ,0.01
SF-36 mental health 84 (68-92) 76 (65-88) 60 (48-76)*‡ ,0.01
All data presented as median (interquartile range). Data were analysed by the Kruskal–Wallis, Dunn multiple comparison test, or Mann–Whitney U test.
Symbols reflect the differences between the respective groups.
* P , 0.01 between no neuropathic pain (NeuP) and moderate/severe NeuP.
† P , 0.05 between mild NeuP and moderate/severe NeuP.
‡ P , 0.01 between mild NeuP and moderate/severe NeuP.
§ P , 0.05, between no NeuP and mild NeuP.
BPI, Brief Pain Inventory; DAPOS, Depression, Anxiety, and Positive Outlook Scale; ISI, Insomnia Severity Index; ONLS, Overall Neuropathy Limitations Scale; PASS-20, short form of Pain Anxiety Symptoms Scale; PCS, Pain
Catastrophizing Scale; SAS, Survey of Autonomic Symptoms; SF-36, short form 36 of the MOS Outcomes Study.
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rationalise further phenotyping of painful diabetic neuropathy, for
instance to optimise clinical trial outcomes. Future prospective
studies will be needed to evaluate how sensory phenotype
evolves over time in relation to DPN and NeuP.
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